Health knowledge and news provided by doctors.

Ads by Google

Child Health and Safety

Vaccine Study To Help Prevent Most Common Viral Causes Of Childhood Respiratory Illness

MedImmune is dosing at-risk children six months to 24 months of age in a Phase 1 trial of a vaccine designed to help prevent respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV-3) infections.

Health and Wellness: